secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001213900-26-047743
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Phase 2a EVERLAST-A meets primary endpoint: 63.5% PASI 100 at Week 16 in psoriasis
--------------------------------------------------------------------------------

- ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 vs 4.8% placebo (p<0.0001), exceeding primary endpoint.
- Secondary endpoints: PASI 90 82.5%, IGA 0 63.5%, IGA 0/1 84.1% vs 4.8% placebo.
- Safety: well-tolerated; no serious TEAEs, no discontinuations; URI 19% vs 14% placebo.
- Updated Phase 1 PK/PD data support once-yearly dosing; concentrations above effective trough for 52 weeks.
- Longer-term EVERLAST-A data (Week 28, 52-wk) expected 2H 2026; EVERLAST-B Phase 2b data expected 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390026047743/0001213900-26-047743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390026047743/ea0287782-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-047743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer